ADI wins SBIR Phase II grant to commercialize novel antigens

The $3 million grant will fund efforts to further develop Antigen Discovery’s (ADI) protein microarray based serodiagnostic platform for applications in biodefense and emerging infectious diseases.

ADI will collaborate with investigators at the Proteomics Core facility of the Pacific Southwest Regional Center of Excellence, located at the University of California (UCI), Irvine.

Huw Davies, principal investigator on the SBIR grant, said: “By using our novel protein array systems and statistical algorithms, we can rapidly discover antigen sets that will provide serological tests that discriminate between different infections, or even between different stages of the same infection.”